We are live on
!
Find out more
Loomis, Sayles & Company Portfolio holdings
AUM
$74.3B
1-Year Est. Return
24.01%
This Fund
S&P 500
This Quarter
Est. Return
+10.76%
1 Year Est. Return
+24.01%
3 Year Est. Return
+109.67%
5 Year Est. Return
+145.58%
10 Year Est. Return
+623.12%
AUM
$82.5B
AUM Growth
+$5.26B
(+6.8%)
Cap. Flow
-$2.02B
Cap. Flow
% of AUM
-2.45%
Top 10 Holdings %
Top 10 Hldgs %
38.94%
Holding
962
New
129
Increased
342
Reduced
292
Closed
136
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$429M |
| 2 |
Airbnb
ABNB
|
+$235M |
| 3 |
T-Mobile US
TMUS
|
+$156M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$139M |
| 5 |
CRISPR Therapeutics
CRSP
|
+$111M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Deere & Co
DE
|
+$488M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$222M |
| 3 |
Expeditors International
EXPD
|
+$191M |
| 4 |
Qualcomm
QCOM
|
+$187M |
| 5 |
CERN
Cerner Corp
CERN
|
+$171M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.12% |
| 2 | Consumer Discretionary | 15.99% |
| 3 | Communication Services | 13.72% |
| 4 | Healthcare | 12.84% |
| 5 | Industrials | 11.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Merit Medical Systems
MMSI
$5.32B
| $53.3M | 0.06% |
824,413
+65,046
| +9% | +$4.02M |
|
127
Evertec
EVTC
$1.78B
| $53.1M | 0.06% |
1,215,763
+112,911
| +10% | +$4.77M |
|
128
Ares Management
ARES
$30.9B
| $53.1M | 0.06% |
834,298
+32,893
| +4% | +$1.84M |
|
|
ENV
129
DELISTED
ENVESTNET, INC.
ENV
| $53M | 0.06% |
698,383
-14,163
| -2% | -$1.04M |
|
130
Apple
AAPL
$4.57T
| $52.7M | 0.06% |
384,716
-41,114
| -10% | -$5.33M |
|
131
MKS Inc
MKSI
$20.6B
| $52.5M | 0.06% |
294,915
+11,089
| +4% | +$2.01M |
|
132
Natera
NTRA
$46.4B
| $52M | 0.06% |
458,095
-137,913
| -23% | -$14.1M |
|
133
Inspire Medical Systems
INSP
$1.74B
| $51.6M | 0.06% |
267,168
-89,163
| -25% | -$17.7M |
|
134
CryoPort
CYRX
$762M
| $51.6M | 0.06% |
817,782
+52,221
| +7% | +$2.94M |
|
135
Globant
GLOB
$1.61B
| $51.6M | 0.06% |
235,341
-4,694
| -2% | -$1.03M |
|
|
P
136
Everpure Inc
P
$29.9B
| $51.6M | 0.06% |
2,640,843
+6,129
| +0.2% | +$121K |
|
137
PJT Partners
PJT
$4.38B
| $51.3M | 0.06% |
718,310
-14,527
| -2% | -$1.04M |
|
138
Vertiv
VRT
$105B
| $51.2M | 0.06% |
1,874,836
+39,314
| +2% | +$940K |
|
|
AXON
139
Axon Enterprise
AXON
$46.4B
| $50.5M | 0.06% |
285,624
+11,178
| +4% | +$1.65M |
|
|
WLL
140
DELISTED
Whiting Petroleum Corporation
WLL
| $50.1M | 0.06% |
917,692
-1,447,559
| -61% | -$62.2M |
|
141
EPAM Systems
EPAM
$5.03B
| $50.1M | 0.06% |
97,969
+3,628
| +4% | +$1.7M |
|
142
Supernus Pharmaceuticals
SUPN
$2.77B
| $49.9M | 0.06% |
1,619,065
+1,186,742
| +275% | +$36.4M |
|
143
AeroVironment
AVAV
$9.45B
| $49.8M | 0.06% |
497,482
+54,421
| +12% | +$5.99M |
|
144
Stoneridge
SRI
$213M
| $49.6M | 0.06% |
1,681,016
+121,260
| +8% | +$3.84M |
|
145
Phreesia
PHR
$773M
| $48.6M | 0.06% |
792,340
-16,031
| -2% | -$835K |
|
146
Patrick Industries
PATK
$2.85B
| $48.3M | 0.06% |
991,728
-20,040
| -2% | -$1.15M |
|
147
Insulet
PODD
$9.79B
| $47.9M | 0.06% |
174,316
+6,668
| +4% | +$1.81M |
|
|
SKX
148
DELISTED
Skechers
SKX
| $47.8M | 0.06% |
959,073
+92,707
| +11% | +$4.37M |
|
149
Popular Inc
BPOP
$11.1B
| $47.7M | 0.06% |
635,308
+10,524
| +2% | +$806K |
|
150
RBC Bearings
RBC
$18B
| $47.6M | 0.06% |
238,537
-4,766
| -2% | -$941K |
|
Similar funds
CBU
BC
Loomis, Sayles & Company's Q2 2021 Portfolio in Review
As of Q2 2021, Loomis, Sayles & Company held 962 positions worth $82.5B, up 6.8% from $77.2B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Loomis, Sayles & Company's Q2 2021 filing shows 129 new, 342 increased, 292 reduced and 136 closed positions. Its largest new stake was Alnylam Pharmaceuticals: 946,065 shares worth $160M. The largest sale was Deere & Co, an estimated $488M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 25% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Loomis, Sayles & Company's largest Q2 2021 buy was Alnylam Pharmaceuticals: 946,065 shares worth $160M.
- Loomis, Sayles & Company added most to Vertex Pharmaceuticals in Q2 2021, an estimated $429M increase.
- Loomis, Sayles & Company's biggest Q2 2021 reduction was Deere & Co, cutting an estimated $488M.
- Loomis, Sayles & Company fully exited Goosehead Insurance in Q2 2021, selling an estimated $66.6M.
- Loomis, Sayles & Company's ten largest holdings make up 39% of its $82.5B portfolio in Q2 2021.
- Loomis, Sayles & Company opened 129 new positions and closed 136 in Q2 2021.
- Loomis, Sayles & Company's portfolio value rose 6.8% quarter-over-quarter to $82.5B.
Based on Loomis, Sayles & Company's 13F filing for Q2 2021, filed 13 Aug 2021.